ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Systemic Lupus Erythematosus

The ACR Helps Diversify Lupus Research

  |  

While African Americans and Hispanics—especially women in these ethnic groups—are disproportionately affected by lupus, they are under-represented in clinical trials in lupus and other chronic diseases.1,2 With the help of a new federal grant, the ACR took the first step to address this lack of diversity in lupus trials this year. The ACR’s Collaboration Initiatives…

Atacicept Shows Promise in Lupus Treatment Trials

  |  

A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…

Studies Find More Evidence the Microbiome Affects Autoimmune Disease

  |  

Evidence is accumulating that the microbiome may be an important part of the pathogenesis of many autoimmune diseases. Two recently published articles report on how translocation of the gut bacterium Enterococcus gallinarum drives autoimmunity in mice and humans, and on the role of other commensal bacteria in triggering immune responses—specifically to the autoantigen Ro60, which…

New Study Works Toward Better Lupus Classification Criteria

  |  

In 1982, the ACR developed classification criteria for the identification of systemic lupus erythematosus (SLE) for use in research. The ACR updated these criteria in 1997, and in 2012, the Systemic Lupus International Collaborating Clinics (SLICC) group developed an additional set of classification criteria. In 2014, in an attempt to establish and refine even more…

SLE Is a Leading Cause of Death Among Women

  |  

Systemic lupus erythematous (SLE) is a chronic inflammatory disease that predominantly affects women and can involve virtually any organ. The authors of this study analyzed secular trends and population characteristics associated with SLE mortality. Objective: Mortality statistics from the Centers for Disease Control and Prevention (CDC) are used for planning healthcare policy and allocating resources….

COIN Launches Playbook to Reach Young Adult Audiences

  |  

The ACR’s Collaborative Initiatives (COIN) department develops and tests innovative solutions for complex rheumatology care problems. “All of the work COIN does—programs toward health equity, creating models to increase rheumatology-related capacity in places of need, building bridges with local and national patient organizations—is done on [behalf of its members],” says Dr. David Daikh. Each month…

Phase 3 Trial Results: Blisibimod for Lupus Shows Possible Efficacy

Renée Bacher  |  

A phase 3 clinical trial in which researchers treated lupus patients with blisibimod, a biologic treatment that inhibits B cell activating factor (BAFF), did not meet its primary endpoint, but did demonstrate evidence of possible efficacy. Researcher Joan T. Merrill, MD, a member of the Oklahoma Medical Research Foundation (OMRF) and OMRF professor of medicine…

Epratuzumab May Work for SLE Subgroups

Larry Beresford  |  

A recent analysis of the monoclonal antibody epratuzumab finds new evidence for its effectiveness in a subset of systemic lupus erythematosus (SLE) patients who have a concurrent diagnosis of Sjögren’s syndrome, a progressive autoimmune disease that affects exocrine glands and is characterized by dry eyes and mouth.1 Sjögren’s can be primary, meaning independent of other…

Study Finds Young Adults with Lupus at High Risk for Depression

Elizabeth Hofheinz, MPH, MEd   |  

As if the fatigue, joint pain, etc., were not enough, new research has found many lupus patients must contend with clinical depression as well—something that can have a devastating cascade effect on other areas of their lives. Are adults with childhood-onset lupus at greater risk of depression than lupus patients with onset of disease during…